Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07742696
Starting soon Not applicable

Comparison of Postoperative Functional Outcomes Between Subvastus and Medial Parapatellar Approach in Total Knee Arthroplasty

NCT07742696 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Not applicable
Started
2026-07-15
Last updated
2026-08-03

Condition(s) studied

Osteoarthritis (OA) of the Knee

Investigational drug(s) / intervention(s)

subvastusmedial parapatellar

subvastus: Patients receive total knee arthroplasty with subvastus approach to expose the knee joint.

medial parapatellar: Patients receive total knee arthroplasty with medial parapatellar approach to expose the knee joint

Study summary

This study aims to compare the effects of the medial parapatellar approach (MP) and the subvastus approach (SV) on postoperative clinical function in total knee arthroplasty (TKA). A total of 84 patients, who visit the Joint Surgery Department of Peking University Third Hospital and are diagnosed with end-stage knee osteoarthritis and require unilateral, primary total knee arthroplasty, will be recruited. The patients will be randomly assigned to two groups, with 42 patients in each group. TKA will be performed using the MP and SV approaches respectively. Postoperative data such as quadriceps muscle strength, the time of first unassisted straight leg raise (SLR), joint range of motion (ROM), KSS score, WOMAC score, SF-12 score, VAS score, and shear wave elastography (SWE) of the medial thigh muscle will be collected. The patients will be followed up for 2 years postoperatively to compare the short-term and long-term clinical functional outcomes of the two surgical approaches.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 50 to 80 who are diagnosed with end-stage knee osteoarthritis that require unilateral primary total knee arthroplasty; * Patients who are determined by clinical and laboratory tests to have no absolute surgical contraindications; * Patients with good compliance, willing and able to undergo follow-up observations as required and sign the informed consent form; Exclusion Criteria: * Patients with a history of surgery on the affected knee joint in the past; * Patients with neuromuscular diseases; * Patients scheduled for knee joint replacement revision surgery; * Patients with active knee joint infection or systemic infection; * Patients who receive primary joint replacement due to non-knee osteoarthritis, such as rheumatoid arthritis, tuberculous arthritis, traumatic arthritis, etc; * Patients with valgus or varus deformity of the knee joint greater than 15°; * Patients with knee flexion deformity greater than 15°; * Patients whose heart and lung functions are determined by clinical and laboratory tests to be unable to tolerate surgery; * Patients with mental disorders who are unable to cooperate with treatment; * Patients who is lactating or pregnant; * Patients who are unwilling to participate in this study and did not sign the informed consent form; * Patients with poor compliance and inability to cooperate in completing the follow-up observers at critical times; * For any reason, the researchers believe that the subject is unlikely to complete this study.

Primary outcome measure(s)

  • Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) — From enrollment to the end of follow-up at 2 years after receiving total knee arthroplasty
    The higher the score, the more severe the symptoms and the worse the postoperative functional recovery.
  • Knee Society Score(KSS) — From enrollment to the end of follow-up at 2 years after receiving total knee arthroplasty
    The lower the score, the more severe the symptoms and the worse the postoperative functional recovery.
  • Short Form 12 Health Survey Questionnaire(SF-12) — From enrollment to the end of follow-up at 2 years after receiving total knee arthroplasty
    The higher score equals to the better postoperative satisfaction.
  • First Unassisted Straight Leg Raise(SLR) — From enrollment to the end of follow-up at 2 years after receiving total knee arthroplasty
    Record the time of the first postoperative unassisted straight leg raise of every patient.

Trial sites (1)

FacilityCityRegionStatus
Orthopaedic Department of Peking University Third Hospital Beijing Haidian

More Peking University Third Hospital trials in China

Shared Medical Appointment for COPD Patients (SMA-COPD) Active, not recruiting
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE) Recruiting
Multi-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison Recruiting
The Cohort Construction Project of Peking University Third Hospital Recruiting
Autologous Osteo-periosteal Cylinder Graft Transplantation for Hepple V Osteochondral Lesions of the Talus Enrolling by invitation

Other trials for the same condition

The Effects of Knee Brace and Muscle Training on Osteoarthritis Patients Enrolling by invitation
Cohort of Lower-Extremity Sports Injuries and Degeneration(Yongjiang Cohort) Recruiting
Clinical Study of Acupuncture Treatment of Knee Osteoarthritis Recruiting
ASKC200 for Knee Osteoarthritis Pain Active, not recruiting
A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07742696 on ClinicalTrials.gov ↗ ← All trials in China